Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen Completed Phase 3 Trials for Flu caused by Influenza Prevention

CompletedPrevention3 IdentifierTitleDrugs
NCT00539981Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok
NCT01959945Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
NCT01825200Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
NCT00539864Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
NCT00395174Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults